FRAMINGHAM, Mass.--(BUSINESS WIRE)--June 14, 2006--GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) announced today that it has received a $1 million payment from LEO Pharma A/S for achieving the milestone of a positive opinion on the market authorization application for ATryn® from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). The CHMP has recommended that ATryn®, GTC’s recombinant form of human antithrombin, be granted market authorization for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency. Final market authorization by the European Commission, which is expected in about three months, will trigger an additional $2 million milestone payment from LEO Pharma.
